TP53 and cancer: Essentially, the underlying molecular mechanism regarding the anti-tumor activity of MDM2 inhibitors in p53 wild-type tumors and, according to the first studies mentioned, also in p53-mutated/p73 wild-type tumors, is based on cancer cell apoptosis induction [14,35].